134 related articles for article (PubMed ID: 31522234)
21. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
[TBL] [Abstract][Full Text] [Related]
22. Prostate Cancer Risk Calculator Apps in a Taiwanese Population Cohort: Validation Study.
Chen IA; Chu CH; Lin JT; Tsai JY; Yu CC; Sridhar AN; Sooriakumaran P; Loureiro RCV; Chand M
J Med Internet Res; 2020 Dec; 22(12):e16322. PubMed ID: 33337340
[TBL] [Abstract][Full Text] [Related]
23. Compliance with biopsy recommendations of a prostate cancer risk calculator.
van Vugt HA; Roobol MJ; Busstra M; Kil P; Oomens EH; de Jong IJ; Bangma CH; Steyerberg EW; Korfage I
BJU Int; 2012 May; 109(10):1480-8. PubMed ID: 21933335
[TBL] [Abstract][Full Text] [Related]
24. A risk calculator to inform the need for a prostate biopsy: a rapid access clinic cohort.
Jalali A; Foley RW; Maweni RM; Murphy K; Lundon DJ; Lynch T; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Durkan GC; Murphy TB; Watson RW
BMC Med Inform Decis Mak; 2020 Jul; 20(1):148. PubMed ID: 32620120
[TBL] [Abstract][Full Text] [Related]
25. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
[TBL] [Abstract][Full Text] [Related]
26. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A
Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258
[TBL] [Abstract][Full Text] [Related]
27. A Calculator for Prostate Cancer Risk 4 Years After an Initially Negative Screen: Findings from ERSPC Rotterdam.
Roobol MJ; Zhu X; Schröder FH; van Leenders GJ; van Schaik RH; Bangma CH; Steyerberg EW
Eur Urol; 2013 Apr; 63(4):627-33. PubMed ID: 22841675
[TBL] [Abstract][Full Text] [Related]
28. Prostate cancer risk assessment tools in an unscreened population.
Lundon DJ; Kelly BD; Foley R; Loeb S; Fitzpatrick JM; Watson RW; Rogers E; Durkan GC; Walsh K
World J Urol; 2015 Jun; 33(6):827-32. PubMed ID: 25091862
[TBL] [Abstract][Full Text] [Related]
29. Adaptation and external validation of the European randomised study of screening for prostate cancer risk calculator for the Chinese population.
Chiu PK; Roobol MJ; Nieboer D; Teoh JY; Yuen SK; Hou SM; Yiu MK; Ng CF
Prostate Cancer Prostatic Dis; 2017 Mar; 20(1):99-104. PubMed ID: 27897172
[TBL] [Abstract][Full Text] [Related]
30. External validation of novel magnetic resonance imaging-based models for prostate cancer prediction.
Püllen L; Radtke JP; Wiesenfarth M; Roobol MJ; Verbeek JFM; Wetter A; Guberina N; Pandey A; Hüttenbrink C; Tschirdewahn S; Pahernik S; Hadaschik BA; Distler FA
BJU Int; 2020 Mar; 125(3):407-416. PubMed ID: 31758738
[TBL] [Abstract][Full Text] [Related]
31. Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports.
Minnee P; Hessels D; Schalken JA; Van Criekinge W
BMC Urol; 2019 Nov; 19(1):124. PubMed ID: 31783839
[TBL] [Abstract][Full Text] [Related]
32. Clash of the calculators: External validation of prostate cancer risk calculators in men undergoing mpMRI and transperineal biopsy.
Wei G; Kelly BD; Timm B; Perera M; Lundon DJ; Jack G; Bolton DM
BJUI Compass; 2021 May; 2(3):194-201. PubMed ID: 35475133
[TBL] [Abstract][Full Text] [Related]
33. Mobile application-based Seoul National University Prostate Cancer Risk Calculator: development, validation, and comparative analysis with two Western risk calculators in Korean men.
Jeong CW; Lee S; Jung JW; Lee BK; Jeong SJ; Hong SK; Byun SS; Lee SE
PLoS One; 2014; 9(4):e94441. PubMed ID: 24710020
[TBL] [Abstract][Full Text] [Related]
34. External validation of the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer risk calculators in a Chinese cohort.
Zhu Y; Wang JY; Shen YJ; Dai B; Ma CG; Xiao WJ; Lin GW; Yao XD; Zhang SL; Ye DW
Asian J Androl; 2012 Sep; 14(5):738-44. PubMed ID: 22561907
[TBL] [Abstract][Full Text] [Related]
35. External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study.
De Nunzio C; Lombardo R; Tema G; Alkhatatbeh H; Gandaglia G; Briganti A; Tubaro A
Urol Oncol; 2018 Aug; 36(8):364.e1-364.e7. PubMed ID: 29880458
[TBL] [Abstract][Full Text] [Related]
36. External Evaluation of a Novel Prostate Cancer Risk Calculator (ProstateCheck) Based on Data from the Swiss Arm of the ERSPC.
Poyet C; Wettstein MS; Lundon DJ; Bhindi B; Kulkarni GS; Saba K; Sulser T; Vickers AJ; Hermanns T
J Urol; 2016 Nov; 196(5):1402-1407. PubMed ID: 27188476
[TBL] [Abstract][Full Text] [Related]
37. An analysis of three different prostate cancer risk calculators applied prior to prostate biopsy: A Turkish cohort validation study.
Yıldızhan M; Balcı M; Eroğlu U; Asil E; Coser S; Özercan AY; Köseoğlu B; Güzel O; Asfuroğlu A; Tuncel A
Andrologia; 2022 Mar; 54(2):e14329. PubMed ID: 34837424
[TBL] [Abstract][Full Text] [Related]
38. Comparison between the European Randomized Study for Screening of Prostate Cancer (ERSPC) and Prostate Biopsy Collaborative Group (PBCG) risk calculators: Prediction of clinically significant Prostate Cancer risk in a cohort of patients from Argentina.
Orbe Villota PM; Leiva Centeno JA; Lugones J; Minuzzi PG; Varea SM
Actas Urol Esp (Engl Ed); 2024 Apr; 48(3):210-217. PubMed ID: 37827241
[TBL] [Abstract][Full Text] [Related]
39. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
[TBL] [Abstract][Full Text] [Related]
40. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
